Repros Therapeutics Inc. (RPRX) Release: American Urological Association (AUA) Accepts Androxal(R) Versus Topical Gel Comparative Study for Podium Presentation at Annual Meeting  
3/25/2013 10:32:36 AM

THE WOODLANDS, Texas, March 25, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the American Urological Association (AUA) has accepted key data on Androxal for presentation at the annual meeting in San Diego, CA, May 4-8th, 2013. The data presented are from a double-blind, placebo and active control study of two doses of Androxal (12.5 and 25mg) with open label on demand Testim gel in 120 patients with secondary hypogonadism over a 3 month period.